Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.
- Lorenzo Leggio
- Christian S. Hendershot
- W. Kyle Simmons
